Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Tax Provisions of $1.0 million for Q1 2026, little changed year-over-year from $1.0 million in Q1 2025, and up 14.94% quarter-over-quarter from $870000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Tax Provisions for 10 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions changed 0.0% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $3.7 million (up 44.99% YoY), while the FY2025 annual figure was $4.0 million, up 100.0% from the prior year.
- Tax Provisions improved to $1.0 million in Q1 2026 per RARE's latest filing, from $870000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $6.3 million in Q3 2022 and bottomed at -$3.9 million in Q4 2023.
- Historically, Tax Provisions has averaged $707411.8 across 5 years, with a median of $650000.0 in 2023.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 3354.4% — and 2023, when it sank 2151.32%.
- Ultragenyx Pharmaceutical's Tax Provisions stood at $189000.0 in 2022, then tumbled by 2151.32% to -$3.9 million in 2023, then jumped by 109.9% to $384000.0 in 2024, then jumped by 126.56% to $870000.0 in 2025, then rose by 14.94% to $1.0 million in 2026.
- Business Quant data shows RARE's Tax Provisions at $1.0 million in Q1 2026, $870000.0 in Q4 2025, and $873000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 870,000.00 |
| Sep 30, 2025 | 873,000.00 |
| Jun 30, 2025 | 947,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 384,000.00 |
| Sep 30, 2024 | 303,000.00 |
| Jun 30, 2024 | 858,000.00 |
| Mar 31, 2024 | 455,000.00 |
| Dec 31, 2023 | -3.88 Mn |
| Sep 30, 2023 | 650,000.00 |
| Jun 30, 2023 | 732,000.00 |
| Mar 31, 2023 | 495,000.00 |
| Dec 31, 2022 | 189,000.00 |
| Sep 30, 2022 | 6.29 Mn |
| Jun 30, 2022 | 302,000.00 |
| Mar 31, 2022 | 558,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 182,000.00 |